BioMarin Pharmaceutical reported Q1 2026 revenues of $766 million, up 3% year-over-year, driven by increased demand for enzyme therapies and new patients on VOXZOGO. Following its acquisition of Amicus Therapeutics, BioMarin raised its full-year 2026 revenue guidance to $3.825-$3.925 billion, reflecting a 20% growth rate at the midpoint. The company highlighted strong pipeline progress, including FDA approvals and upcoming Phase 3 data readouts, positioning it for continued innovation and growth. Despite higher expenses related to the acquisition and R&D, BioMarin expects improved financial performance and expanded patient reach in rare diseases.
Fury Gold Mines has restarted exploration and drilling activities at its Eau Claire project in Northern Quebec following a temporary halt due to a nearby wildfire. All personnel have safely returned, and operations resumed after confirming safe condi...
YieldMax announced weekly distributions for three of its Performance & Distribution Target 25 ETFs: MSST, NVIT, and TEST. Each ETF targets a 25% annual income level, with distributions scheduled for July 29, 2026. These ETFs use a call writing strate...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Dimensional Fund Advisors Ltd. has disclosed ownership of 11,780,819 shares, representing a 1.26% stake in Prologis Inc as of July 24, 2026. This disclosure is made under the Takeover Code, indicating a significant investment position. The firm also ...
Man Group PLC has publicly disclosed holding a 1.63% interest in Senior Plc through cash-settled equity swaps as of July 24, 2026. This disclosure is made under Rule 8.3 of the UK Takeover Code, indicating a significant stake in the company. The posi...
